Free Trial
→ 'Computers are about to become obsolete' - George Gilder. Here’s why. (From Eagle Publishing) (Ad)tc pixel
NASDAQ:HUMA

Humacyte Q1 2026 Earnings Report

Humacyte logo
$0.96 -0.04 (-4.10%)
As of 10:52 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Humacyte EPS Results

Actual EPS
N/A
Consensus EPS
-$0.10
Beat/Miss
N/A
One Year Ago EPS
N/A

Humacyte Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.46 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Humacyte Announcement Details

Quarter
Q1 2026
Date
5/13/2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Humacyte Earnings Headlines

Humacyte Appoints Todd E. Rasmussen, M.D., as Chief Surgical Officer to Advance Clinical Adoption of Symvess®
 |  quiverquant.comQ
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3292739/0/en/humacyte-appoints-dr-todd-e-rasmussen-as-chief-surgical-officer.html
What is "The Final Phase of Elon's Master Plan"?
Hedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 while the S&P returned just 15% - says Elon Musk is preparing to execute what he calls the 'Final Phase' of his master plan. It's not Tesla, SpaceX, crypto, or AI. Benedict believes one overlooked ticker is positioned to capture billions - potentially trillions - when this phase is triggered. He's revealing the name and ticker free today.tc pixel
May 12 at 1:00 AM  |  Brownstone Research (Ad)
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
May 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260508434967/en/humacyte-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-humacyte-inc.---huma/
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026
May 8, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/humacyte-to-announce-2026-first-quarter-financial-results-and-provide-business-update-on-may-13-2026-1036129449
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026
May 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/08/3291035/0/en/humacyte-to-announce-2026-first-quarter-financial-results-and-provide-business-update-on-may-13-2026.html
See More Humacyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Humacyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Humacyte and other key companies, straight to your email.

About Humacyte

Humacyte (NASDAQ:HUMA) is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation. Humacyte is also exploring additional indications, including peripheral and coronary artery bypass and central venous access, with the goal of addressing significant unmet medical needs in cardiovascular surgery and interventional medicine. Research and development efforts are supported by Good Manufacturing Practice (GMP) facilities in the United States, enabling scale-up from laboratory to commercial production.

Founded in 2004 by Dr. Scott B. Rhodes at Duke University, Humacyte is headquartered in Durham, North Carolina, with ongoing clinical programs and partnerships extending into Europe and North America. The company is led by a management team with experience spanning cell therapy, regenerative medicine and vascular surgery. Humacyte continues to work alongside clinical investigators and strategic collaborators to advance its HAV technology toward regulatory approval and broad clinical adoption.

View Humacyte Profile
Earnings Tools